Comparative Pharmacology
Head-to-head clinical analysis: NEXTSTELLIS versus SEASONIQUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEXTSTELLIS versus SEASONIQUE.
NEXTSTELLIS vs SEASONIQUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: estrogen (estetrol) and progestin (drospirenone) suppress gonadotropin release, inhibiting ovulation; increase cervical mucus viscosity, impeding sperm penetration; alter endometrial lining, reducing implantation likelihood.
Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) that inhibits ovulation by suppressing gonadotropin-releasing hormone (GnRH), follicle-stimulating hormone (FSH), and luteinizing hormone (LH); increases cervical mucus viscosity and alters endometrial receptivity.
One tablet orally once daily, each tablet containing drospirenone 3 mg and estetrol 14.2 mg, taken continuously without a break.
One tablet daily orally: 84 days of ethinyl estradiol 0.02 mg / levonorgestrel 0.1 mg (active), followed by 7 days of ethinyl estradiol 0.01 mg.
None Documented
None Documented
Drospirenone: 30 hours; ethinyl estradiol: 12 hours. The long half-life allows once-daily dosing and stable serum concentrations.
Ethinyl estradiol: approximately 15.9 hours (range 9-28 hours); Levonorgestrel: approximately 24.4 hours (range 12-48 hours). Terminal elimination half-life accounts for steady-state attainment within 5-7 days.
Urine (60%) and feces (35%); drospirenone and metabolites, with enterohepatic recirculation.
Renal: approximately 60% (as glucuronide and sulfate conjugates); Fecal: approximately 40% (as metabolites, with enterohepatic recycling).
Category C
Category C
Contraceptive
Contraceptive, Combination Hormonal